Rx Bandz MiniJect handles advanced hydrogels in Notre Dame test

Rx Bandz and the University of Notre Dame’s Webber Lab showed that the MiniJect auto-injector can deliver advanced supramolecular hydrogels at practical speeds while keeping injection forces acceptable. The result points to broader use for high-viscosity therapies in regenerative medicine and cell-based treatments.

Why it matters: - The test expands the range of injectable therapies that can be delivered with an auto-injector. - High-viscosity, shear-thinning, and self-healing biomaterials are often hard to administer with conventional devices. - Better delivery compatibility can reduce risk, improve consistency, and support translation of regenerative medicine and cell-based therapies. - The work also supports drug-device combination products designed for next-generation treatments.

What happened: - The University of Notre Dame’s Webber Lab and Rx Bandz demonstrated that the MiniJect auto-injector could deliver advanced supramolecular hydrogels at practical injection speeds. - The tests showed acceptable injection forces during delivery. - The hydrogels were used as a model for advanced soft biomaterials that can carry therapeutic cells or drugs. - The collaboration was announced Aug. 4, 2026, from Denville, New Jersey.

The details: - Supramolecular hydrogels are water-rich biomaterials being developed for regenerative medicine and drug delivery. - These materials temporarily become less viscous during injection and then rapidly recover their structure. - That behavior makes them useful for minimally invasive therapies, but difficult for many conventional auto-injector systems. - Rx Bandz is evaluating MiniJect with advanced formulations, including high-viscosity injectables and other non-Newtonian materials. - The company is positioning the platform to support broader drug-device combination products. - The Webber Lab is led by Prof. Matthew Webber, who is the Keating-Crawford Collegiate Professor of Engineering, professor of chemical and biomolecular engineering, and acting director of the Berthiaume Institute for Precision Health at Notre Dame. - The lab pioneered the supramolecular hydrogel used in the collaboration. - The lab describes itself as an interdisciplinary research group focused on molecular engineering for healthcare and welcomes industry partnerships. - Learn more about the Webber Lab at the Webber Lab. - Rx Bandz is a privately held medical device and formulation development company based in Denville, New Jersey. - The company is developing patient-centric auto-injectors and proprietary drug formulations. - MiniJect is being developed for emergency medications including epinephrine, ketamine, hydromorphone, tranexamic acid, and antibiotics. - Rx Bandz says the platform is designed for prehospital, battlefield, home, and everyday settings. - The company is also developing a family of auto-injectors for 1 mL to 5 mL injectable therapies across a broad range of viscosities. - More information is available at Rx Bandz. - The release also includes social links to Rx Bandz on LinkedIn and Rx Bandz on Facebook.

Between the lines: - The result suggests device design can be a bottleneck, not just drug formulation, when advanced injectables move toward real-world use. - The collaboration signals an effort to match new biomaterials with delivery hardware earlier in development. - That pairing can help reduce failures when therapies move from lab settings into clinical use.

What's next: - Rx Bandz said it will keep evaluating MiniJect with additional advanced formulations. - The company is continuing work on next-generation drug-device combination products. - Further device and biomaterial testing could broaden which injectable therapies can be delivered without specialized settings.

The bottom line: - MiniJect’s ability to deliver a challenging supramolecular hydrogel suggests auto-injectors may be able to handle more complex therapies than many current systems.